Progressive Exercise for Anabolism in Kidney Disease

• Register: ANZCTR
• Last refreshed on: 13 January 2020
• Main ID: ACTRN12605000101684
• Date of registration: 09/08/2005
• Prospective Registration: No
• Primary sponsor: Kidney Health Australia
• Public title: Progressive Exercise for Anabolism in Kidney Disease
• Scientific title: A randomized phase III study to evaluate the effects of progressive resistance training in the treatment of muscle wasting to improve physical function and quality of life in end stage renal disease
• Date of first enrolment: 01/10/2002
• Target sample size: 50
• Recruitment status: Active, not recruiting
• URL: https://anzctr.org.au/ACTRN12605000101684.aspx
• Study type: Interventional
• Study design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Crossover;Type of endpoint: Safety/efficacy;
• Phase: Phase 1

Countries of recruitment

Australia

Contacts

• Name: Maria Fiatarone Singh

• Name: Maria Fiatarone Singh

Key inclusion & exclusion criteria

Inclusion criteria: Stable hemodialysis patients with no contraindications to progressive resistance training.
Exclusion criteria: No exclusion criteria

Age minimum: Not stated
Age maximum: Not stated
Gender: Both males and females

Health Condition(s) or Problem(s) studied

End stage renal disease;
End stage renal disease

Renal and Urogenital - Other renal and urogenital disorders

Musculoskeletal - Other muscular and skeletal disorders

Intervention(s)

The experimental grroup will receive progressive Resistance Training for 24 weeks in addition to usual care.

Primary Outcome(s)

Skeletal muscle cross-sectional area and attenuation[Measured at baseline, week 12 and week 24]

Secondary Outcome(s)

C-reactive protein[Measured at baseline, week 12 and week 24.]

Dialysis Adequacy (Kt/V)[Measured at baseline, week 12 and week 24.]

Geriatric Depression Scale (GDS)[Measured at baseline, week 12 and week 24.]

Static balance[Measured at baseline, week 12 and week 24.]

Haemotological markers[Measured at baseline, week 12 and week 24.]

Isometric muscular strength[Measured at baseline, week 12 and week 24.]

Mini-nutritional assessment (MNA),[Measured at baseline, week 12 and week 24.]

Protein Catabolic Rate[Measured at baseline, week 12 and week 24.]

Physical Activity Scale for the Elderly (PASE)[Measured at baseline, week 12 and week 24.]

Dietary Intake (Australian Food Frequency Questionnaire).[Measured at baseline, week 12 and week 24.]

6-minute walk[Measured at baseline, week 12 and week 24.]

Quality of Life (SF-36)[Measured at baseline, week 12 and week 24.]

Source(s) of Monetary Support

University of Sydney

Simbex Technologies

NHMRC

Kidney Health Australia

Secondary Sponsor(s)

University of Sydney

Ethics review

Status: Not approved
Approval date:
Contact:

RPAH

Status: Not approved
Approval date:
Contact:

SESAHS

Status: Not approved
Approval date:
Contact:

USYD